978 material Form 8-K filings that 854 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5).
Brady Corporation said two new directors, Scott J. Robinson and Kenneth J. Spangler, joined its Board effective November 9, 2026, and that director Patrick W. Allender will retire and not stand for re-election at the upcoming Annual Shareholders' Meeting. Robinson joins the Audit Committee and Spangler joins the Technology Committee, and each will receive a $160,000 stock award. The filing is a board composition change and does not report financial results or guidance.
Scott J. Robinson and Kenneth J. Spangler join the Board effective November 9, 2026; both were elected November 6, 2026.
Patrick W. Allender, who served 19 years on the Board, notified the Board on November 6, 2026 of his retirement.
Robinson joins the Audit Committee and Spangler joins the Technology Committee.
Each new director will receive a $160,000 fair value award of unrestricted Class A Nonvoting Common Stock, dated November 9, 2026.
News Corp filed two daily buy-back notices with the Australian Securities Exchange covering open-market repurchases of its Class A and Class B common stock on November 6, 2026, under its program authorized at up to $1 billion. The filing states that $574,365,655 has been paid under the program to date, so the company continues to reduce its share count, which matters to shareholders because repurchases can support per-share measures.
Class A: 28,539 shares bought on November 6, 2026 for $754,208.71; 14,191,858 shares for $377,171,863.40 before that day.
Class B: 12,422 shares bought on November 6, 2026 for $362,018.07; 6,548,856 shares for $196,077,565.27 before that day.
The filing says $574,365,655 has been spent under the $1 billion program authorized July 15, 2025.
Reported price ranges: Class A $22.20 (February 9, 2026) to $31.58 (August 27, 2026); Class B $25.49 (February 13, 2026) to $35.69 (August 27, 2026).
Precision BioSciences said it expects its November 5, 2026 share offering, along with existing cash, its at-the-market facility and continued cost discipline, to fund operations into the fourth quarter of 2029. The company projects it is sufficiently capitalized to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key next-stage inflection points. The filing does not state the net proceeds amount.
Offering of 10,235,077 common shares at $7.75 per share, under an underwriting agreement dated November 5, 2026
Pre-funded warrants for up to 5,893,964 shares offered in lieu of common stock to certain investors, at $7.749995 per warrant
Expected cash runway into the fourth quarter of 2029, covering PBGENE-HBV and PBGENE-DMD programs
ProKidney reported cash and marketable securities of $141.9 million as of September 30, 2026, in a filing that also furnished an updated investor presentation. The filing contains no revenue, net loss or per-share figures, so the cash balance and the company's stated runway are the main financial disclosures for shareholders.
Cash and marketable securities were $141.9 million as of September 30, 2026.
The updated investor presentation says current cash is expected to support operating plans into mid-2027.
The presentation lists the Phase 3 PROACT 1 topline readout for Q2 2027 and a BLA submission for Q1 2028.
The filing does not include revenue, net income or loss, or earnings per share.
Walker & Dunlop published a November 9, 2026 investor presentation on its Investor Relations website, furnished as Exhibit 99.1 under Regulation FD and not deemed filed. The deck cites a $146.6 billion servicing portfolio as of September 30, 2026, a $62 million remaining share buyback authorization, and net debt to adjusted EBITDA of 2.8x, giving shareholders a snapshot of the company's capital position. The 8-K text itself reports no new quarterly financial results.
Presentation published November 9, 2026 and dated the same day as Exhibit 99.1
Servicing portfolio of $146.6 billion at September 30, 2026, a 2% increase year to date
$62 million share buyback authorization remaining and net debt to adjusted EBITDA of 2.8x (trailing twelve months)
Presentation cites about $20 million of run-rate fixed expense reduction starting in Q2 2027
WaFd, Inc. disclosed a November 2, 2026 letter agreement with Chief Experience Officer Cathy E. Cooper providing a $1,650,000 lump-sum payment tied to the pending merger with EverBank Financial Corp. Cooper must remain employed through the merger closing to receive it, and in exchange she will waive certain good reason triggers under her change of control agreement arising from her transition to a new role at the surviving company.
Lump-sum Continuity Payment of $1,650,000, payable within 60 days after the Merger closes
Payment requires Cooper's continued employment through the Closing
Cooper waives certain good reason triggers under her change of control agreement effective at Closing
Merger Agreement with EverBank Financial Corp was signed September 6, 2026
Abeona Therapeutics acquired APT-1011, now called ABO-801, a clinical-stage treatment candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals in exchange for 4,494,383 common shares valued at $20 million, with no upfront cash. The company also agreed to sell 6,400,000 shares and pre-funded warrants for 1,600,043 shares in a private placement for about $30 million, expected to close November 10, 2026, which will add new shares and dilute existing holders.
Ellodi receives 4,494,383 shares valued at $20 million, based on a 20-day VWAP ending the trading day before the November 6, 2026 closing date, and no upfront cash.
Further payments to Ellodi include $30 million upon FDA approval of a New Drug Application, up to $30 million on sales milestones, and tiered royalties in the low to mid teen percentages.
Private placement of 6,400,000 shares at $3.75 per share plus pre-funded warrants at $3.7499, with Morgan Stanley as sole placement agent and net proceeds for general corporate purposes including ZEVASKYN.
One-third of the upfront shares unlock at each of the 6-, 12- and 18-month anniversaries of closing; resale registration for the private placement shares is due within 15 days after closing.
National Healthcare Properties increased its board from six to eight directors and elected Jeffrey S. Olson and Craig S. Smith, effective November 9, 2026, to fill the new seats. Olson joined the CCG Committee and Smith joined the Audit Committee, and the Board deemed both independent.
Board expanded from six to eight directors on November 6, 2026; Olson and Craig S. Smith elected effective November 9, 2026
Jeffrey S. Olson is Chairman and CEO of Urban Edge Properties and was appointed to the CCG Committee
Craig S. Smith is CEO of Aimbridge Hospitality and was appointed to the Audit Committee
SBA Communications entered a $2.0 billion senior unsecured Term Loan Credit Agreement on November 6, 2026. The company intends to use the $1.165 billion of initial term loans, funded at closing, to repay its Secured Tower Revenue Securities, Series 2021-1C, while $835.0 million of delayed draw commitments remain available until May 6, 2027.
Total facility of $2.0 billion: $1.165 billion funded on November 6, 2026 and $835.0 million of delayed draw term loan commitments
Initial term loans will repay the entire $1.165 billion of Secured Tower Revenue Securities, Series 2021-1C
Term loans mature November 6, 2029, do not amortize and can be prepaid without premium or penalty
Covenants include a Consolidated Total Net Leverage Ratio not to exceed 7.50 to 1.00 and a Consolidated Senior Secured Leverage Ratio not to exceed 3.50 to 1.00
Canton Strategic Holdings announced that the first trades of its issuer-sponsored tokenized common stock occurred on November 4, 2026, on TSV LLC's venue on the Canton Network, under the SEC's September 17 Innovation Exemption. The filing contains no financial results, guidance, or financial figures; it describes a new trading and recordkeeping arrangement for the company's shares.
First tokenized CNTN trades executed November 4, 2026 on TSV LLC, with Five North as seller, DRW Cumberland as buyer and Flowdesk as liquidity provider.
Fairmint TA LLC, the company's SEC-registered transfer agent, records the tokenized shares; holders must be verified before holding or trading.
Tokenized shares carry the same rights as CNTN stock traded on Nasdaq, according to the company, and trading is available 24/7 on the venue, subject to stated limits.
Charles River Laboratories agreed to acquire the bioanalysis and DMPK operations of Frontage Holdings in Exton, Pennsylvania, for approximately $470 million in cash, plus up to $75 million in performance-based payments. The company expects the deal to be neutral to non-GAAP earnings per share in 2027 and accretive after that, and expects to close in the first half of 2027, subject to shareholder and regulatory approvals.
Purchase price of approximately $470 million in cash, subject to customary closing adjustments, with additional payments of up to $75 million tied to future performance
Acquired businesses represented approximately 40% of Frontage's 2025 revenue of $256.7 million and employ approximately 340 people across two Exton sites
Expected to be neutral to non-GAAP EPS in 2027 and accretive thereafter; to be financed through Charles River's credit facility and available cash
Closing expected in the first half of 2027; Frontage is being taken private by a consortium that includes Tigermed and Dr. Song Li
Hawaiian Electric Industries furnished an investor presentation under Regulation FD for use with investors and analysts beginning on or after November 9, 2026. The deck mainly restates prior financial, regulatory and wildfire-recovery positions and does not report new quarterly results or change guidance.
Presentation furnished as Exhibit 99 and posted at www.hei.com; the filing states it is not deemed filed under the Exchange Act
Utility LTM Core ROE was 5.2% as of 9/30/2026, per a slide footnote; the Company's rate rebasing request is for a 5.3% base rate increase
PUC Phase 6 timeline: parties' replies to the Staff Proposal are due Nov. 13, and a final decision is preliminarily scheduled for mid-to-late April 2027
Liquidity was $1,324 million at 3Q 2026, and the presentation cites a $558 million equity issuance
Cabaletta Bio released new Phase 1/2 clinical data on its investigational cell therapy rese-cel, presented at the ACR Convergence 2026 meeting, covering dermatomyositis, lupus nephritis, and systemic sclerosis patients followed up to one year. The company reported that 100% (6/6) of dermatomyositis patients maintained immunomodulator-free responses through one year, and it reiterated plans for registrational topline results in the second half of 2027 and a planned BLA submission in the first quarter of 2028. The sample sizes are small, and the filing does not report any financial figures.
100% (6/6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year
71% (5/7) of systemic sclerosis patients achieved rCRISS-50 at one year; five patients with interstitial lung disease showed 9% mean FVC improvement
Grade 2 cytokine release syndrome was reported in 6% (4/71) of 71 patients; no IEC-HS was reported
Registrational topline results expected in 2H 2027; planned BLA submission in myositis in 1Q 2028
Vistance Networks CEO Chuck Treadway, who has led the company since October 2020, will step down as President, CEO and board member effective February 1, 2027, after resigning on November 4, 2026. The board has launched a search for a successor and retained an executive search firm, and Treadway's severance is contingent on signing a separation agreement with a general release.
Treadway resigned November 4, 2026 and leaves the CEO role and board on February 1, 2027.
Treadway's departure is treated as a resignation for good reason under his Severance Protection Agreement, with severance contingent on a separation agreement containing a general release.
The company says it returned $16.50 per share to shareholders through special cash distributions in 2026, including a $1.50 per share distribution payable November 6, 2026.
The company released third quarter 2026 results in a separate press release issued the same day, November 5, 2026.
Corebridge Financial entered into a Share Repurchase Agreement with Argon Holdco LLC on November 6, 2026, to repurchase its common stock for an aggregate purchase price of approximately $110 million. The price is $34.09 per share, the November 6 New York Stock Exchange closing price, and the repurchase is expected to close on November 10, 2026, subject to customary closing conditions.
Per-share price of $34.09, equal to the NYSE closing price on November 6, 2026
Aggregate purchase price of approximately $110 million
Expected closing on November 10, 2026, subject to customary closing conditions
Agreement is with Argon Holdco LLC and is filed as Exhibit 10.1
FTAI Aviation's subsidiary issued $1.0 billion of 7.125% Senior Notes due November 15, 2034, on November 6, 2026. Net proceeds will repay its revolving credit facility, which was used to fund the parent's accelerated share repurchase program, and redeem $500.0 million of 5.50% notes due 2028.
Proceeds: repay in full the Revolving Credit Facility without a reduction in commitments, redeem $500.0 million of 5.50% Senior Notes due 2028, and pay fees
Notes are senior unsecured, fully guaranteed by FTAI Aviation Ltd., and offered only to qualified institutional buyers and non-U.S. persons
Valion Bio, Inc. issued 700 Series B Preferred Shares and warrants for 21,539 common shares to investor 3i, LP for $700,000 on November 6, 2026, under a side letter to an earlier agreement. The company also agreed to register the resulting common shares for resale and extended the deadline for further closings to December 9, 2027, which may add future dilution for shareholders.
Closing purchase price: $700,000 for 700 Series B Preferred Shares and warrants
Warrants cover 21,539 shares of common stock at an initial exercise price of $0.5182 per share
Registration statement to be filed within 30 days after closing and declared effective within 60 days
Outside date for closings under the Series B Preferred Purchase Agreement extended to December 9, 2027
Datavault AI's board appointed Brett Moyer as Chief Executive Officer and President, effective immediately, after Nathaniel Bradley was removed from that role on November 1, 2026. Board changes also name Kimberly Briskey Chair and Teresa Gallo Chief Operating Officer, a shake-up that bears on how the company is run and governed.
Brett Moyer, previously CFO and a director, named CEO and President effective November 6, 2026; Nathaniel Bradley removed as CEO on November 1, 2026
Stanley Mbugua, previously Chief Accounting Officer, named Chief Financial Officer; Teresa Gallo named Chief Operating Officer
Kimberly Briskey named Chair of the Board; Christopher R. Hardt named Chair of the Audit Committee
Company says it will report third-quarter 2026 results on a date to be announced
Randolph C. Read resigned from the board of Roman DBDR Acquisition Corp. II, along with its audit and compensation committees, effective immediately, on November 4, 2026. The filing states his resignation was not due to any disagreement with the company on operations, policies or practices, and the board named Bryn Sherman and Hunter Gary to fill the committee vacancies.
Randolph C. Read resigned from the board, audit committee and compensation committee on November 4, 2026, effective immediately
Bryn Sherman appointed chairperson of the Compensation Committee, effective November 4, 2026
Hunter Gary appointed as a member of the Audit Committee, effective November 4, 2026
Filing states the resignation was not the result of any disagreement with the company
Mount Logan Capital appointed Brandon Harper as its Chief Accounting Officer and principal accounting officer, effective November 3, 2026. Brandon Satoren, the company's CFO, no longer serves as principal accounting officer, though he remains CFO.
Brandon Harper, age 33, appointed by the board on November 3, 2026, previously served as Group Controller from July 2026.
Harper received 7,080 restricted stock units on November 6, 2026, vesting in three equal installments on January 1, 2027, 2028 and 2029.
Brandon Satoren, Chief Financial Officer, no longer serves as principal accounting officer as of November 3, 2026.
The filing notes potential conflicts of interest with BC Partners Advisors L.P., the company's servicing agent and holder of a minority equity interest through an affiliate.
T3 Defense Inc. completed its acquisition of KeepZone AI Inc. on November 4, 2026, paying by issuing 425,594 shares of common stock to the seller, Nexera Technologies Ltd. An amendment to the purchase agreement raised the purchase price to $1,539,800 and lifted the seller's beneficial ownership limit in the company to 9.9%. The company said the deal was not a significant acquisition, so separate KeepZone financial statements are not required.
Purchase price raised to $1,539,800 under the amendment dated November 4, 2026
425,594 new common shares issued to Nexera Technologies Ltd. as consideration
Seller's beneficial ownership limit in T3 Defense raised to 9.9%
Company states the acquisition was not significant under Item 2.01 of Form 8-K
Shuttle Pharmaceuticals Holdings dismissed Forvis Mazars, LLP as its independent registered public accounting firm and engaged Bush & Associates CPA LLC on November 2, 2026. Bush & Associates will audit the fiscal year ending December 31, 2026, and review interim financial statements through September 30, 2027. The filing states no disagreements or reportable events with the former auditor.
Forvis Mazars dismissal was approved by the Audit Committee and full Board, effective after the Form 10-Q for the quarter ended September 30, 2026, as previously reported October 21, 2026.
Bush & Associates CPA LLC was engaged on November 2, 2026, under an engagement letter dated October 19, 2026.
Bush & Associates will audit fiscal 2026 and review interim quarters ending March 31, June 30 and September 30, 2027.
The company states there were no consultations with Bush & Associates on accounting matters and no disagreements or reportable events in fiscal 2024, fiscal 2025 or the interim period through November 2, 2026.
Mangoceuticals' sole Series B preferred holder approved terms for a new 8% Series D convertible cumulative preferred stock and an amendment to the Series B designation, which would allow the company to sell up to 1,000,000 shares at $10.00 each under Regulation A. The company said the instruments are not yet filed or effective and it may not proceed with the offering; the company also set its combined 2025 and 2026 annual meeting for December 30, 2026.
On November 2, 2026, the holder of all 50 outstanding Series B preferred shares approved the Series D terms and Series B amendment by written consent.
Proposed Series D offering: up to 1,000,000 shares at $10.00 per share under Regulation A; no sales will occur before the SEC qualifies the offering statement on Form 1-A.
Annual meeting set for December 30, 2026 in Dallas, Texas; record date is November 12, 2026.
Shareholder proposals and director nominations for the meeting are due by November 16, 2026.
BioVie Inc. agreed on November 3, 2026 to sell shares and pre-funded warrants in a registered direct offering and common warrants in a concurrent private placement, with aggregate gross proceeds of approximately $4.74 million before fees and expenses. The offering closed on November 5, 2026, and the company intends to use the net proceeds for working capital and general corporate purposes. The deal adds shares and dilutive warrants, and the company has agreed to restrictions on new share issuances.
Registered direct offering: 960,000 shares at $1.60 per share plus 2,002,500 pre-funded warrants at $1.5999 each
Concurrent private placement: 2,962,500 common warrants exercisable at $1.70 per share, starting six months after issuance
Placement agent A.G.P./Alliance Global Partners receives a cash fee of 7.0% of gross proceeds
Company and directors and officers agreed to issuance and sale restrictions for 60 days after the November 5, 2026 closing
Kontoor Brands completed the sale of its H.D. Lee Company subsidiary to ABG-Storm LLC, an affiliate of Authentic Brands Group, on November 2, 2026. The company received $750 million in cash at closing, subject to post-closing adjustments, plus up to $250 million in earnout payments tied to the Lee business's performance over five years. The filing says the company anticipates using $400 million for accelerated share repurchases and $50 million for open market repurchases.
Closing date: November 2, 2026; cash at closing of $750 million before post-closing adjustments
Pro forma estimate of cash received after adjustments: approximately $698.2 million
Earnout of up to $250 million over five years; estimated fair value at closing of $77.0 million
Planned use of proceeds: $400 million in accelerated share repurchases and $50 million in open market repurchases
HeartSciences filed an 8-K with supplemental disclosures to its proxy statement for the proposed merger with Fortitude Mining Holdings, a subsidiary of Digital Currency Group. The company received seven demand letters from purported shareholders alleging the proxy omits material information, and says the claims are without merit but is voluntarily adding disclosures to avoid delays and litigation expense. The special meeting remains scheduled for November 19, 2026, so the disclosures do not change the vote timing.
Seven demand letters received from counsel to purported shareholders alleging proxy omissions.
Company denies the allegations and says disclosures are voluntary, made without admitting liability.
Supplemental disclosures include a January 6, 2026 letter of intent with Fortitude and an indicated equity value range for Fortitude of $206.0 million to $428.2 million.
Special Meeting to be held virtually on November 19, 2026, at 10:00 a.m. Eastern Time.
First Breach announced a supplier agreement giving it the ability to purchase up to 20 million primers per month, two additional ammunition inspection units, and a separate raw material supply agreement. The company says these steps support plans to scale ammunition production toward up to 20 million rounds per month and move toward 24-hour operations.
Primer agreement allows purchases of up to 20 million primers per month from a strategic supplier
Two additional ammunition inspection units added, supplementing equipment acquired earlier this year at the Hagerstown, Maryland facility
Separate raw material supply agreement announced; no financial terms, dollar values or contract durations were disclosed
Filing is a Regulation FD disclosure furnishing the November 3, 2026 press release; no financial results were reported
TuHURA Biosciences borrowed an additional $1.5 million on November 2, 2026, under the revolving credit facility from its April 21, 2026 Loan Agreement with Parkview Holdings One LLC. The facility has a maximum availability of $50 million and matures on April 21, 2031, and the company says it will use the funds for general corporate purposes.
Draw of $1,500,000 received and borrowed on November 2, 2026
Revolving facility with Parkview Holdings One LLC has maximum availability of $50 million
Facility matures April 21, 2031; the Loan Agreement was originally entered into April 21, 2026
Filing notes potential conflicts of interest because the lender is an affiliate of the company's largest stockholder
NorthWestern Energy filed a presentation for the EEI Financial Conference in Scottsdale, Arizona, November 8-10, 2026, in which executives will affirm the company's 2026 non-GAAP earnings guidance of $3.68 to $3.83 per diluted share. The filing reports no new financial results and no change to guidance, and the guidance excludes costs related to the pending merger with Black Hills Corp.
2026 non-GAAP EPS guidance of $3.68 to $3.83 per diluted share is affirmed, not changed
Presentation dated November 8, 2026, furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Exchange Act
Presenters are CEO Brian Bird, CFO Crystal Lail, and Travis Meyer, director of corporate development and investor relations
The presentation cites a $3.21 billion five-year capital plan and a Montana final order on the Black Hills merger expected by November 12, 2026
Lazard filed a prospectus supplement covering the possible resale of up to 9,416,817 common shares issued to sellers in its previously announced acquisition of Campbell Lutyens Holdings Limited. The filing is administrative and sets up potential sales of these shares by the selling stockholders, which could add to the number of shares available in the market.
Prospectus supplement under Rule 424(b) filed November 6, 2026, covering up to 9,416,817 shares of common stock
Sullivan & Cromwell LLP opinion on share validity filed as Exhibit 5.1
Data Storage Corporation said director Harold J. Schwartz resigned from its Board of Directors, effective immediately, after notifying the Board on November 4, 2026. The company said the resignation was not due to any disagreement over its operations, policies or practices, and that Mr. Schwartz did not serve on any Board committee.
Harold J. Schwartz resigned as a Board member, effective immediately
Notice to the Board was given on November 4, 2026; the 8-K was dated November 6, 2026
Company states no disagreement with management on operations, policies or practices
Mr. Schwartz previously served as an officer of former subsidiary CloudFirst Technologies Corporation and sat on no Board committee
Santander Holdings USA, Inc. (SHUSA) said it will redeem all 6,000 outstanding shares of its Series H Preferred Stock and the corresponding 6,000,000 depositary shares on December 15, 2026. Depositary shares will be redeemed at $25.00 each, and the redemption price excludes the regular quarterly dividend, which is payable separately on the same date to holders of record on November 30, 2026.
Redemption date: December 15, 2026, covering 6,000 preferred shares and 6,000,000 depositary shares.
Redemption price: $25.00 per depositary share, not including the declared quarterly dividend.
Quarterly dividend: $0.328125 per depositary share, payable December 15, 2026 to holders of record as of November 30, 2026.
Redemption agent: Broadridge Corporate Issuer Solutions, LLC; shares are held through DTC.
BCP Investment Corporation postponed the release of its third quarter 2026 financial results and the related conference call, which were originally scheduled for November 5 and November 6, 2026. The company said the delay gives management more time to finalize financial disclosures, regulatory filings and structural terms tied to a potential strategic initiative, and that there is no assurance this will lead to a definitive agreement or transaction.
Q3 2026 results release and conference call postponed from November 5 and November 6, 2026
Delay tied to finalizing disclosures, regulatory filings and structural terms of a potential strategic initiative
Company states the delay is not related to any accounting, financial or regulatory matters
New call date and dial-in details to be issued by separate press release in the coming days
RPM International's Chairman and CEO Frank C. Sullivan announced on November 6, 2026 that he plans to retire within the next twelve to eighteen months. He will remain in his role until a successor is appointed and is expected to then stay on as Chair of the Board, as the company runs a succession planning process with its Board.
Frank C. Sullivan plans to retire in the next twelve to eighteen months, per the November 6, 2026 filing.
Sullivan has served nearly 25 years as Chairman and CEO and more than 40 years with the company.
He will remain CEO until his successor is appointed and is expected to stay on as Board Chair afterward.
Delta Air Lines completed a public offering of $500 million in 5.500% notes maturing November 6, 2029, on November 6, 2026. The company said it will use part of the proceeds to repay about $391 million of Payroll Support Program loan borrowings, about $70 million of aircraft-secured equipment notes, and, with cash on hand, about $39 million of pass through certificates, with any remainder for general corporate purposes. The filing adds new unsecured debt to the balance sheet while reducing several existing obligations.
Notes: $500 million aggregate principal, 5.500% coupon, maturing November 6, 2029
Interest paid semi-annually on May 6 and November 6, starting May 6, 2027
Proceeds to repay about $391 million Payroll Support Program loan, about $70 million equipment notes, and about $39 million pass through certificates
American Healthcare REIT entered into a new at-the-market equity sales agreement allowing it to sell up to $1.75 billion of common stock through a group of sales agents and forward purchasers. The company terminated its prior program, which had about $170 million left unsold, and says it will use any net proceeds for general corporate purposes, which may include future investments.
Agreement allows sales of common stock with an aggregate gross sales price of up to $1,750,000,000, replacing the prior program dated February 27, 2026.
About $170,134,000 remained unsold under the prior sales agreement when it was terminated.
Agents may receive a commission of up to 2.0% of gross sales price; shares are sold under a shelf registration statement on Form S-3 dated August 12, 2024.
Proceeds would go to the Operating Partnership for general corporate purposes, which may include potential future investments.
Victory Capital filed an 8-K with supplemental disclosures to its proxy statement for the planned acquisition of First Eagle, which it says it made voluntarily to reduce the risk of litigation delaying the deal. Two stockholder lawsuits and a number of demand letters allege the proxy statement was materially incomplete and misleading, and Victory says those claims are without merit. The company states the supplemental disclosures do not change the consideration or the timing of the November 17, 2026 special meeting.
Base purchase price for First Eagle is $7.03 billion, subject to adjustment, including a reduction for First Eagle's funded debt and other debt-like items.
Share consideration is valued at $2 billion based on $116.26 per share and represents 4.9% of Victory's outstanding common stock after issuance.
Two complaints were filed in New York Supreme Court on October 27 and October 28, 2026, and plaintiffs seek to enjoin the deal or seek rescission or damages.
The special meeting of Victory stockholders is scheduled for November 17, 2026, and the board still recommends voting FOR the proposals.
Silgan signed a consent to its credit agreement with Wells Fargo as administrative agent, letting lenders designate a new subsidiary, Silgan Metal Packaging LLC, as an unrestricted subsidiary. The change supports the planned contribution of several container and closure businesses to that entity under the October 17, 2026 Transaction Agreement. The filing gives no financial results or deal value, so the near-term effect on shareholders is not quantified here.
Consent to Amended and Restated Credit Agreement dated November 6, 2026, with Wells Fargo Bank, National Association, as Administrative Agent
Silgan Metal Packaging LLC (MetalCo) to be designated an Unrestricted Subsidiary, releasing it as a guarantor under the credit agreement
Business Contribution tied to the Transaction Agreement dated October 17, 2026 with A-VL Holdco, LP
If the MetalCo Transactions do not close, MetalCo and its subsidiaries will cease to be Unrestricted Subsidiaries
Hyatt Hotels filed a Regulation FD disclosure on lock-up restrictions covering its Class A and Class B shares. Based on current agreements, 14,685,256 restricted shares held by Pritzker family stockholders will be available for public sale from November 5, 2026 through November 4, 2027, which could add supply to the stock market.
14,685,256 restricted shares held by Pritzker family stockholders may be sold from November 5, 2026 to November 4, 2027
2,270,395 additional restricted Class B shares held by other 2007 Stockholders' Agreement parties are available for sale at any time, subject to Company rights of first refusal
An additional 2,678 restricted shares are not subject to lock-up restrictions
Nexentis Technologies Inc. effected a 1-for-5 reverse stock split of its common stock, under authority approved by stockholders on April 30, 2026. The split took effect at 4:15 p.m. Eastern Time on November 6, 2026, and the stock will trade on a split-adjusted basis on the Nasdaq Capital Market from November 9, 2026, under the existing symbol NXTS. The company said the split is intended to raise the per-share price and bid price to regain compliance with Nasdaq continued listing requirements.
Every 5 outstanding shares converted into 1 share; per-share exercise prices and option and warrant share counts adjusted proportionately
Outstanding shares to fall from approximately 2.9 million to approximately 600 thousand, per the press release
Trading begins on a split-adjusted basis November 9, 2026, under new CUSIP 80512Q709
Authorized common stock unchanged at 495,000,000 shares; fractional shares rounded up to the next whole share
D. Boral Acquisition I Corp., a British Virgin Islands blank-check company, disclosed that director Benjamin Piggott resigned from its board on September 23, 2026, saying the decision was not related to any disagreement with the company. The board appointed Kevin McGurn and Luisa Ingargiola to its Audit and Compensation Committees, with McGurn also named Compensation Committee chair. The changes are board administration and do not include any financial or operational figures.
Benjamin Piggott resigned from the board, effective with notice to the board on September 23, 2026
Kevin McGurn appointed to the Audit Committee and named Compensation Committee chair, effective September 23, 2026
Luisa Ingargiola appointed to the Compensation Committee, effective September 23, 2026
McGurn reassigned from Class I to Class II director; his term expires at the second annual shareholder meeting
Fractyl Health's board increased its size from nine to ten and appointed Michael Wartell as an independent Class III director effective November 2, 2026. Wartell will receive $40,000 per month in cash compensation under a director agreement, with a minimum of three months guaranteed unless he resigns.
Michael Wartell appointed effective November 2, 2026; term expires at the 2027 annual meeting
Cash compensation of $40,000 per month, payable monthly in advance, with a three-month minimum unless he resigns
Additional $3,000 for each day Board commitments exceed four hours outside normal Board duties
Wartell has not been appointed to any Board committee and will not join the Non-Employee Director Compensation Policy
Cantor Fitzgerald Income Trust, Inc. declared its October 2026 distributions on November 6, 2026, at an annual rate of 5.00% of net asset value per share class. The filing lists gross distributions for each share class, with Class I shares at $0.089263 and Class D shares at $0.089221, payable on or about November 6, 2026 to holders of record as of October 31, 2026. The filing states that some or all of the cash distributions may be paid from sources other than cash flow from operations.
Gross distribution per Class I share: $0.089263; Class D: $0.089221; Class S and Class T: $0.089178
Annual rate: 5.00% of net asset value per share class
Record date: October 31, 2026; payment date: on or about November 6, 2026
Some or all cash distributions may be paid from sources other than cash flow from operations
Energy Transfer LP priced $2.7 billion of senior notes in three equal $900 million tranches, due 2032, 2037 and 2057, with coupons of 5.450%, 5.900% and 6.550%. The offering is expected to settle on November 20, 2026, and the net proceeds of about $2.68 billion (before offering expenses) are intended to refinance existing debt, including commercial paper and revolving credit facility borrowings, and for general partnership purposes.
Three $900 million tranches: 5.450% notes due 2032, 5.900% notes due 2037 and 6.550% notes due 2057.
Prices to the public were 99.972%, 99.719% and 99.862% of face value, respectively.
Expected settlement date is November 20, 2026, subject to customary closing conditions.
Net proceeds of about $2.68 billion will refinance existing indebtedness and fund general partnership purposes; several underwriters' affiliates are lenders under the revolving credit facility and may receive a share of the repayment.
Enova International said subsidiary OnDeck Asset Securitization IV, LLC intends to offer $500,251,000 of Series 2026-2 fixed rate asset-backed notes in a private securitization backed by small business loans originated or purchased by its subsidiary ODK Capital, LLC. Closing is anticipated on or about November 13, 2026, subject to market and customary conditions, so the offering may not be completed as contemplated or at all. The notes will not be obligations of or guaranteed by Enova or OnDeck, and OnDeck expects to use substantially all proceeds for loan purchases from affiliates and general corporate purposes.
Four classes total $500,251,000: Class A $190,095,000 at 5.81%, Class B $118,744,000 at 6.15%, Class C $100,050,000 at 6.73%, Class D $91,362,000 at 8.57%.
Anticipated Kroll Bond Rating Agency ratings range from AA (sf) for Class A to BB- (sf) for Class D.
Notes are offered only to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S, and are not registered under the Securities Act.
Legal final payment date is December 19, 2033; the company announced the offering on November 3, 2026.
Molina Healthcare said senior management will reaffirm its 2026 full-year GAAP diluted EPS guidance of at least $2.38 and adjusted diluted EPS guidance of at least $5.25 at UBS's Global Healthcare Conference on November 9, 2026. The filing reaffirms existing guidance rather than changing it, so shareholders get no new numbers, but it confirms the company's outlook as of early November.
Reaffirmed 2026 full-year GAAP diluted EPS guidance of at least $2.38
Reaffirmed 2026 full-year adjusted diluted EPS guidance of at least $5.25
Remarks at UBS conference on November 9, 2026 available by webcast at 10:15 a.m. Eastern Time, with a 30-day replay
Roku completed its merger with Fox Corporation on November 6, 2026, becoming a wholly owned subsidiary of FOX. Roku stockholders received $95.30 in cash and 0.9799 of a share of FOX Class A common stock per share, and trading of Roku stock on Nasdaq will halt.
The merger became effective on November 6, 2026, resulting in a change in control.
Stockholders are entitled to $95.30 in cash and 0.9799 of a FOX Class A common stock share per share.
Roku requested the removal of its Class A common stock from listing on Nasdaq.
Roku terminated its existing credit agreement dated September 16, 2024.
ACRES Commercial Realty Corp. entered into a Seventh Amendment to its Master Repurchase and Securities Contract Agreement with Morgan Stanley Mortgage Capital Holdings, which extends the agreement to November 2027 and modifies certain financial covenants in the related guaranty. The filing describes a routine financing amendment and does not disclose a borrowing amount, pricing, or fee figures beyond a reference to an unspecified Extension Fee.
Amendment dated November 2, 2026 extends the Morgan Stanley agreement to November 2027.
Company, as guarantor, agreed to amend certain financial covenants in its guaranty to Morgan Stanley.
Subsidiary ACRES Real Estate SPE 10, LLC is the seller; payment of an Extension Fee was due on or before November 3, 2026, amount not stated in the filing.
Zenas BioPharma filed a new prospectus supplement for an at-the-market offering of up to $200 million in common stock through Jefferies LLC, and ended the earlier program, under which it had sold about $153.2 million of shares with about $46.8 million unsold. The filing is a routine share-sale mechanism, and any sales would dilute existing shareholders, though the filing does not state whether or when any shares will be sold.
New prospectus supplement filed November 6, 2026, for up to $200,000,000 of common stock under the October 8, 2025 Sales Agreement with Jefferies LLC
Prior program terminated: about $153.2 million sold and about $46.8 million unsold at filing date
Shares to be offered under the existing Form S-3ASR registration statement, which became automatically effective upon filing
Ropes & Gray LLP legal opinion filed as Exhibit 5.1
On November 5, 2026, the Public Service Commission of Wisconsin approved rate changes in rate cases filed in April 2026 by Wisconsin Electric Power Company, Wisconsin Gas LLC and Wisconsin Public Service Corporation. The presentation slides attached to the filing list an authorized return on equity of 9.50% and an equity ratio of 53.0%, and say a final written order is expected before year-end.
PSCW approved rate changes on November 5, 2026 for Wisconsin Electric, Wisconsin Gas and Wisconsin Public Service
Authorized return on equity of 9.50% and equity ratio of 53.0%
Earnings sharing: no sharing on the first 15 basis points above the allowed ROE, 50/50 on the next 25 basis points, and 100% to customers beyond 40 basis points
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.